Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667739 | 0.88 | CYP4F2 (0.39) | RENL3MBTL1ALOX5CHRM2CHRM1 | |
| SCHEMBL4669426 | 0.86 | KMT2A (0.41) | RENTSHRALOX5P2RX4ALDH1A1 | |
| SCHEMBL4669242 | 0.86 | REN (0.46) | RENL3MBTL1TSHRALOX5CHRM2 | |
| SCHEMBL4669425 | 0.84 | MEN1 (0.47) | RENTSHRALOX5CHRM2CHRM1 | |
| SCHEMBL4669287 | 0.82 | REN (0.42) | RENL3MBTL1TSHRALOX5CHRM2 | |
| SCHEMBL4670464 | 0.82 | ALOX5 (0.38) | RENL3MBTL1TSHRALOX5CHRM2 | |
| Bromide SCHEMBL11067184 | 0.81 | ALOX5 (0.38) | RENL3MBTL1ALOX5CHRM2CHRM1 | |
| SCHEMBL4221762 | 0.80 | P2RX4 (0.41) | L3MBTL1ALOX5CHRM2CHRM1CHRM3 | |
| SCHEMBL4669085 | 0.78 | ALOX5 (0.36) | RENL3MBTL1ALOX5CHRM2CHRM1 | |
| SCHEMBL15691733 | 0.76 | ALDH1A1 (0.44) | POLBALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| EP-1879882-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885L3MBTL1 4487/4885TSHR 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.